ArticleOncology letters2020

Potential synergistic effects of sorafenib and CP-31398 for treating anaplastic thyroid cancer with p53 mutations.

Jiin-Torng Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.